|

Saruparib (AZD5305) Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: AZD5305, Darolutamide is also known as Nubeqa, Saruparib

Pipeline

Phase 1: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • AstraZeneca4

Indications

  • Cancer4
  • Locally Advanced or Metastatic Solid Tumor1
  • Lung Adenocarcinoma1
  • Advanced Breast Cancer1
  • Endometrial Cancer1

Other1 trial

AZD5305 hADME in Patients With Advanced Solid Malignancies
Phase 1

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Duarte, California1 trial

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Research Site

Phase 1/2

Detroit, Michigan1 trial

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

Research Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.